Abstract:709 Background: Stereotactic body radiotherapy (SBRT) has been incorporated into multi-modality treatment of locally advanced and borderline resectable pancreatic ductal adenocarcinoma (PDAC). For non-metastatic inoperable PDAC patients (pts) who receive magnetic resonance-guided SBRT (MRgSBRT), baseline features that predict for treatment response remain unsettled. In localized PDAC, multiple studies have investigated the KRAS oncogene as a prognostic factor with mixed findings. In this single institution retrospective study of PDAC pts treated with MRgSBRT, we hypothesized that KRAS mutation status would be predictive of meaningful clinical outcomes. Methods: From an IRB approved dataset of PDAC pts treated with MRgSBRT between 2016 and 2022, 39 pts with non-metastatic inoperable pancreatic cancer, known KRAS mutation status, ≥ 3 months of neoadjuvant systemic therapy (NST), and at least 3 months post-RT follow up were extracted for analysis. Baseline demographics, tumor and treatment characteristics, and clinical endpoints including conversion to resectability, best imaging response per RECIST v1.1, pathologic response (PR) per TRG-CAP, and overall survival (OS) after MRgSBRT were collected. Objective response (ORR) on both imaging and pathology was defined as complete response (CR) + partial response (PR); disease control (DC) was defined as CR + PR + stable disease (SD). Logistic regression was used to assess correlation between baseline variables and ORR. Cox proportional hazard models were utilized to determine association with OS. Results: Out of 39 pts, 21 (53%) were KRAS-mutated (KRAS-mt) and 18 (47%) were KRAS wild-type (KRAS-wt). Median age was 62, 54% were male, only 1 pt had ECOG > 1, and CA 19-9 at diagnosis was 197. Median duration of NST was 9 cycles, and common agents included Gemcitabine and Abraxane (21%); FOLFIRINOX (28%); a combination of the two regimens (41%); or other NSTs (10%). Median MRgSBRT dose fractionation was 50 Gy (range 35 – 50) in 5 fractions; all fractions underwent adaptive optimization. Thirty pts (77%) experienced DC on imaging, 16 (43%) had ORR, and 12 (31%) were converted to resectable following MRgSBRT. Cohort median OS was 12.3 months, and pts who had surgery had a non-significant median OS advantage (18 vs 12 months; p=0.19). KRAS-mt was associated with worse ORR (p=0.04; AUC=0.73) and decreased OS (HR: 2.15; p=0.03). In a clinical model incorporating baseline characteristics (age, ECOG, radiographic staging, CA 19-9 level, and KRAS), only KRAS predicted OS (HR: 3.02 for KRAS-mt; p=0.01). KRAS-mt status was also predictive of OS among pts who underwent surgery (HR: 5.24 for KRAS-mt; p=0.04). Conclusions: For localized PDAC pts inoperable at diagnosis who received NST followed by MRgSBRT, KRAS was the only significant predictor of ORR and OS, highlighting the need for further treatment intensification in KRAS-mt pts.

The impact of Kirsten rat sarcoma (KRAS) status on local tumor progression after surgical ablation of colorectal liver metastases

The Association of KRAS Mutation and Primary Tumor Location with Recurrence in Colorectal Liver Metastases Undergoing Radiofrequency Ablation

Different Effects of KRAS Gene on Recurrence for Right- and Left-sided Colorectal Liver Metastases Undergoing Radiofrequency Ablation

The Value of KRAS Gene Status in Predicting Local Tumor Progression of Colorectal Liver Metastases Following Radiofrequency Ablation

Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients with Unresectable Colorectal Liver Metastasis.

Influence Of Kras Mutation Status In Metachronous And Synchronous Metastatic Colorectal Adenocarcinomas

Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis

KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.

Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases

Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?

KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases

Prognostic Impact of KRAS and BRAF Mutations in Patients Who Underwent Simultaneous Resection for Initially Resectable Colorectal Liver Metastases

The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features

Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers

The KRAS G12D mutation increases the risk of unresectable recurrence of resectable colorectal liver-only metastasis

The association between KRAS and histopathological growth patterns and the impact on resection margins around vasculature and bile ducts in colorectal liver metastases

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

Anatomical Resection Improves Relapse-Free Survival in Colorectal Liver Metastases in Patients with KRAS/NRAS/BRAF Mutations or Right-Sided Colon Cancer: a Retrospective Cohort Study.

Clinical Outcomes in Patients With Krukenberg Tumors From Colorectal Cancer

[Study on relationship of the K-ras mutation with the occurrence of colorectal liver metastasis and survival outcomes].